HeartBeam (BEAT)
NASDAQ:BEAT
Want to see BEAT full AI Analyst Report?
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$42.06M
Enterprise Value$22.90M
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 06, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding55,506,836
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-954.09
Enterprise Value/Ebitda-1.14
Forecast
1Y Price Target
$3.90Price Target Upside52.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$1.83M
Bulls Say, Bears Say
Bulls Say
Regulatory FoundationTwo prior FDA clearances create a durable regulatory foundation that supports limited commercial sales today and simplifies incremental indication expansions. Having cleared arrhythmia assessments reduces initial regulatory risk and enables stepwise clinical adoption and reimbursement discussions over months to years.
Strategic AI PartnershipA formal collaboration with Mount Sinai strengthens HeartBeam's technical moat by accelerating algorithm development using high-quality clinical data. This partnership can materially improve diagnostic performance, speed regulatory acceptance of AI features, and make the product stickier for institutional customers over the medium term.
Extended Runway Via FinancingA successful $11.5M financing materially extends operational runway, allowing the company to complete clinical pilots, advance the patch prototype, and fund a focused commercial rollout. Improved liquidity reduces near-term capital risk and supports execution on regulatory and commercialization milestones.
Bears Say
Pre-revenue ProfileSustained zero reported revenue and multi-year operating losses indicate the business has not yet demonstrated commercial scalability. Over months this keeps the company dependent on external funding and makes long-term sustainability contingent on successful customer conversion and recurring subscription adoption.
Weakened Balance SheetA materially depleted equity cushion limits financial flexibility and increases dilution or refinancing risk if execution slips. Shrinking shareholder capital reduces the firm's ability to absorb setbacks and raises the importance of hitting near-term clinical and commercial milestones to avoid additional fundraising that could dilute stakeholders.
Limited Commercial TractionRelying on a few anchor customers and undisclosed patient counts concentrates commercial risk: slower-than-expected conversions or limited penetration per account would delay revenue curvature. A deliberately lean sales model may conserve cash but could slow adoption velocity and postpone achieving a stable recurring revenue base.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $42.06M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Aug 06, 2026 which is in 50 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.135 by $0.015.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.09.
How many shares outstanding does HeartBeam have?
HeartBeam has 55,506,836 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.135. Following the earnings report the stock price went up 2.97%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.90 (52.34% Upside)
$3.90 (52.34% Upside)
Insider Transactions
Bought Shares
Worth $905.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-1034.04%
Trailing 12-Months
Asset Growth
-56.86%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc. is a medical technology firm specializing in remote cardiac care. The company provides telemedicine solutions designed to diagnose and monitor heart conditions outside of traditional healthcare facilities. Their offerings empower physicians with vital diagnostic data, enabling effective management of patients with cardiovascular disease. At the core of their telehealth product is a compact, credit card-sized electrocardiogram (ECG) device, seamlessly integrated with a cloud-based diagnostic software platform. This innovative system addresses the rapidly expanding need for remote patient monitoring. HeartBeam, Inc. was established in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational progress across multiple fronts — financing closed to extend runway, prototype completion and pilot initiations for the 12‑lead patch, enrollment momentum in ALIGN‑ACS, strategic Mount Sinai AI collaboration, and initial commercial anchor partnerships in four target geographies. At the same time, the company remains an early‑stage commercial operation with a Q1 net loss of $4.7M, limited near‑term revenue, reliance on future studies and regulatory approvals for MI indication, and continued cash consumption (though operating cash burn improved 19% YoY and full‑year outflow guidance was reduced to under $16M). On balance, the highlights (funding, clinical progress, partnerships, prototype, AI collaboration, reduced burn) outweigh the lowlights (losses, limited revenue, regulatory and adoption risk), yielding a cautiously positive outlook as the company advances toward de‑risking key milestones.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$3.90
▲(52.34% Upside)
Technical Analysis
Ownership Overview
10.47% Insiders
2.61% Mutual Funds
1.69% Other Institutional Investors
81.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---